Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancer

Abiraterone (generic) is indicated 'with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)'.

The dosage schedule is available in the summary of product characteristics for abiraterone.

The list price of abiraterone varies by pack size or dose (BNF online, accessed September 2025).

Costs may vary in different settings because of negotiated procurement discounts.

For information, a Carbon Reduction Plan for UK carbon emissions is not included because there are multiple companies that manufacture abiraterone.